title: Suppression of myoclonus in corticobasal degeneration by levetiracetam.
abstract: Myoclonus in corticobasal degeneration (CBD) has often been associated with severe and difficult to treat disabilities. Levetiracetam is a new antiepileptic agent with antimyoclonic effects. Herein, we present a 72-year-old woman with clinically probable CBD and with spontaneous rhythmic myoclonus in the right foot, which was markedly ameliorated through treatment with levetiracetam. The effect of levetiracetam was associated with the decreased amplitude of enlarged cortical somatosensory evoked potentials. This result suggests that the antimyoclonic effect of levetiracetam might be mediated through the suppression of increased cortical excitability.
authors.affiliation: Department of Neurology, Pusan National University Yangsan Hospital, Yangsan, Korea.
authors.forename: Jae Wook
authors.initials: JW
authors.lastname: Cho
authors.affiliation: Department of Neurology, Pusan National University Yangsan Hospital, Yangsan, Korea.
authors.forename: Jae Hyeok
authors.initials: JH
authors.lastname: Lee
keywords: Corticobasal degeneration; Levetiracetam; Myoclonus